scholarly journals Recurrent ascites in systemic lupus erythematosus treated with rituximab - a case report and review of pseudo-pseudo Meigs’ syndrome

2021 ◽  
Vol 3 (1) ◽  
Author(s):  
Sarah Compton ◽  
Sarah Luebker ◽  
DeAnna Baker Frost

Systemic lupus erythematosus (SLE) is a chronic autoimmune and inflammatory disease with multisystem consequences. Pseudo-pseudo Meigs’ syndrome (PPMS), or Tjalma syndrome, is a newly recognized manifestation of SLE that is characterized by increased CA-125 level, pleural effusion, and ascites without evidence of tumor. PPMS is relatively rare and likely under-recognized. To our knowledge, there are 11 published case reports about PPMS. In nearly half of the PPMS cases, ascites is the initial symptom of SLE. The pathophysiology of this syndrome is not completely understood but thought to be in part due to chronic inflammation, which is supported by symptoms abating with immunosuppression. We report a case of a 20-year-old woman with known SLE who developed recurrent large volume ascites, subsequently leading to the diagnosis of PPMS, requiring rituximab for additional immunosuppression. To our knowledge, this is the first case of using rituximab as a successful treatment for PPMS.

Reumatismo ◽  
2019 ◽  
Vol 71 (2) ◽  
pp. 108-112 ◽  
Author(s):  
G. Tansir ◽  
P. Kumar ◽  
A. Pius ◽  
S.K. Sunny ◽  
M. Soneja

Systemic lupus erythematosus (SLE) is a chronic inflammatory multisystem autoimmune disease. Ascites when associated with pleural effusion and raised CA-125 levels in SLE patient, is known as pseudo-pseudo Meigs’ syndrome (PPMS). This is the case of a 22-year-old lady who presented with complaints of abdominal distension for one month and had a history of spontaneous abortion in the past. Abdominal imaging did not reveal any tumor and after extensive workup a diagnosis of PPMS was made. She was successfully treated with steroids, hydroxychloroquine and cyclophosphamide.


2019 ◽  
pp. 28-31
Author(s):  
Rosana Quintana ◽  
M. Emilia Sattler ◽  
Marisol Ferrer

A 59-year-old male patient with a diagnosis of systemic lupus erythematosus and pulmonary consolidation associated with mediastinal polyadenopathies and pleural effusion, with chronic and torpid evolution. Differential dignoses and clinical implications are discussed.


Author(s):  
Elias Quintero-Muñoz ◽  
María Alejandra Gómez Pineda ◽  
Carolina Araque Parra ◽  
Camilo Alfonso Vallejo Castillo ◽  
Víctor Ortega Marrugo ◽  
...  

2020 ◽  
Vol 000 (000) ◽  
pp. 1-6
Author(s):  
Fatima Magzoub Mohamed Khatieb ◽  
Sara Hamza Abushama ◽  
Mohammed Elmujtba Adam Essa Adam ◽  
Shaima N. Elgenaid ◽  
Abdelkareem A. Ahmed ◽  
...  

2019 ◽  
Vol Volume 11 ◽  
pp. 117-119
Author(s):  
Vadood Javadi Parvaneh ◽  
Mohsen Jari ◽  
Sheri Motahari ◽  
Khosro Rahmani ◽  
Reza Shiari

2018 ◽  
Vol 4 (2) ◽  
pp. 205521731876833 ◽  
Author(s):  
Elisa Carolina Jácome Sánchez ◽  
María Ariana García Castillo ◽  
Victor Paredes González ◽  
Fernando Guillén López ◽  
Edgar Patricio Correa Díaz

Multiple sclerosis (MS) and systemic lupus erythematous (SLE) are autoimmune diseases, the coexistence of which is uncommon in patients. Owing to the rarity of this condition, the distinction between MS and SLE is a diagnostic challenge for neurologists. We present a case report in which MS and SLE were present in the same patient. There are few case reports in the world on the association between MS and SLE. The following case report is the first of its kind in which both MS and SLE are present in a patient from a country with low prevalence of MS such as Ecuador.


2021 ◽  
pp. 089719002110532
Author(s):  
Morgan E. Ragsdale ◽  
Lisa G. Hall Zimmerman

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that commonly manifests as cutaneous rashes, renal disease, gastrointestinal dysfunction, and cytopenia. Hematological anomalies are frequently associated with drug-induced toxicity in SLE patients. Colony-stimulating factors have been used to treat drug-induced cytopenia in past case reports; however, evidence suggests that colony-stimulating factors can exacerbate autoimmune disorders, including SLE. This case report presents two patients with SLE exacerbations after colony-stimulating factor administration. The first case is a young male with SLE who developed pancytopenia with a white blood cell count (WBC) of 1 × 109 cells/L. The patient was administered filgrastim during his initial admission and presented to the hospital 2 days after discharge in cardiac arrest with a WBC of 66.7 × 109 cells/L. The second case is a 49-year-old female with SLE who was administered sargramostim in response to a WBC count of 9 × 109 cells/L. The patient experienced a drastic increase in WBC followed by a cardiac arrest. These cases highlight the need for more research regarding the safe use of colony-stimulating factors in SLE patients.


2016 ◽  
Vol 20 (2) ◽  
pp. 139-141
Author(s):  
AliMohammed Al-Sheikh ◽  
Khalid Mohammed Al Attas ◽  
Mohammed A. Buraik ◽  
Amr Mohammed Gamal ◽  
Mohammad Kamrul Ahsan

Sign in / Sign up

Export Citation Format

Share Document